Bellicum Pharmaceuticals Inc (BLCM) CTO Sells $70,400.00 in Stock
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) CTO David M. Spencer sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $7.04, for a total value of $70,400.00. Following the completion of the transaction, the chief technology officer now directly owns 89,939 shares of the company’s stock, valued at approximately $633,170.56. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of BLCM stock remained flat at $$6.25 on Friday. The stock had a trading volume of 539,479 shares, compared to its average volume of 334,293. The firm has a market capitalization of $270.93 million, a PE ratio of -2.20 and a beta of 0.54. The company has a current ratio of 10.24, a quick ratio of 10.24 and a debt-to-equity ratio of 0.32. Bellicum Pharmaceuticals Inc has a 12 month low of $5.02 and a 12 month high of $13.30.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.05). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.08 million. equities analysts forecast that Bellicum Pharmaceuticals Inc will post -2.37 earnings per share for the current year.
A number of equities analysts have issued reports on the company. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 10th. BidaskClub cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. Citigroup lowered their target price on Bellicum Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating for the company in a report on Thursday, August 9th. Finally, Cantor Fitzgerald set a $18.00 target price on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.48.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.